This deficiency is linked to the MS‐associated genetic risk variant rs12487066, which enhances binding of the repressive transcription factor C/EBPβ to the CBLB gene, thereby lowering Cbl‐b expression, impairing immune tolerance, and altering T cell responses to viral triggers [368]. The gene discussed is CBLB; the disease is myeloid sarcoma.